I am a medical oncologist who specializes in the treatment of patients with soft tissue and bone sarcomas. Sarcomas are rare tumors that affect individuals of all ages and can develop in almost every organ in the body. At Memorial Sloan Kettering Cancer Center, we have a multidisciplinary team of physician-scientists, nurses, and patient support advocates who care for individuals with sarcoma. Our dedicated team is very familiar with and understands the nuances of these uncommon and challenging malignancies. This enables us to focus on the specific needs of each patient with an emphasis on personalized medicine that benefits from clinical and basic science research.
My research efforts are directly related to the clinical needs of my patients. I have a large clinical practice, I develop and run clinical trials that evaluate the use of new anticancer treatments, and I have a strong focus on laboratory research that strives to better understand the genetic origins of sarcoma. It is my mission to ensure that all patients who come to our clinics receive comprehensive and individualized care that is designed at the forefront of medicine.
- Clinical Expertise: Soft Tissue and Bone Sarcoma; Drug Development
- Awards and Honors: New York Magazine Top Doctors (2015, 2016)
- Languages Spoken: English
- Education: MD, Jefferson Medical College
- Residencies: Vanderbilt University Medical Center
- Fellowships: University of California, Los Angeles (UCLA) Medical Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by William D. Tap
Clinical Trials Co-Investigated by William D. Tap
- A Phase I Study of AG-881 to Treat Advanced Solid Tumors, including Gliomas, that Contain Mutated IDH1 or IDH2
- A Phase I Study of Oral AG-120 in Patients with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation
- A Phase IB Study of Gemcitabine and Docetaxel with Olaratumab in Patients with Advanced Soft Tissue Sarcoma
- A Phase Ib/II Study of MEK162 with Imatinib in Patients with Untreated Advanced Gastrointestinal Stromal Tumor
- A Phase II Study of Abemaciclib for Dedifferentiated Liposarcoma
- A Phase II Study of Efatutazone versus Placebo for Previously Treated Inoperable Myxoid Liposarcoma
- A Phase II Study of Immunotherapy with Nivolumab, with or without Ipilimumab, in Patients with Metastatic or Inoperable Sarcoma
- A Phase II Study of Mocetinostat plus Gemcitabine in Patients with Persistent or Recurrent Leiomyosarcoma
- A Phase IIB Study of NY-ESO-1 T-Cell Immunotherapy in Patients with Advanced Myxoid/Round Cell Liposarcoma
- A Pilot Study of Genetically Engineered NY-ESO-1-Specific T Cells in Children and Adults with Persistent Synovial Sarcoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more